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Introduction 
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1. INTRODUCTION 
 
1.1 ANALYTICAL METHODS (Alexeyev, 2004) 
Analytical chemistry is a science concerned with development of the 
theoretical foundations and methods of chemical analysis.  The practical objective of 
analytical chemistry is to establish the chemical composition of substances or their 
mixtures. 
The task of analytical chemistry can be solved with the aid of a variety of methods, 
either by chemical, physical, physio-chemical methods. These methods are 
continuously expanded and perfected. More advanced techniques of analysis are 
continuously designed, which require new procedures and new theoretical 
substantiation. Analytical chemistry can be divided into two areas called qualitative 
analysis and quantitative analysis. The detection or identification of individual of 
elements or ions entering into the composition of a substance constitutes the task of 
qualitative analysis. The determination of the quantitative content of constituents of 
the substance under study is the aim of quantitative analysis. 
 
1.1.1 Classification of Analytical Methods (Gary D. Christian, 2005) 
                       Many available techniques possess varying degrees of selectivity, 
sensitivity, accuracy & precision, cost and rapid. 
1. Gravimetric Analysis 
2. Volumetric / Titrimetric analysis 
3. Instrumental analysis 
A) Spectrophotometry 
1.   Ultraviolet spectroscopy 
2.   Visible Spectrophotometry 
3.    IR spectroscopy 
B) Fluorimetry 
C) Atomic Spectroscopy 
1. Absorption 
2. Emission 
D) Nuclear Magnetic Resonance Spectroscopy(NMR) 
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E) X-ray spectroscopy 
1. Absorption 
2. Fluorescence 
F) Electro analytical chemistry 
1. Potentiometry 
2. Voltammetry 
G) Chromatography 
1. Gas 
2. Liquid 
H) Radio chemistry 
 
1.1.2 Stages of Analysis (Mendham et al., 2002) 
                   A complete chemical analysis, even for a single substance, involves a 
series of steps and procedures. These steps assessed in order to minimize errors and to 
maintain accuracy and reproducibility. 
The steps are 
1. Sampling 
2. Preparation of Analytical sample 
3. Dissolution of sample 
4. Removal of interference 
5. Sample measurement and control of Instrumental factors. 
6. Results 
7. Presentation of data. 
 
1.1.2 Factors Affecting the Choice of Analytical Method (Mendham et al., 2002) 
                     Analytical techniques have different degrees of sophistication, sensitivity 
and selectivity as well as different cost and time requirements.  An important task for 
the analyst is to select the best procedure for a given determination.  This will require 
careful consideration of the following criteria. 
1. The type of analysis required elemental or molecular, routine or occasional. 
2. Problems arising from the nature of the material to be investigated. 
3. The concentration range to be investigated 
4. The accuracy required. 
5. The facilities available, particularly the instruments. 
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1.2 ULTRAVIOLET SPECTROSCOPY 
Introduction (Kalsi, 2007; Sharma, Y.R. 2007; Fifield et al., 2004) 
Ultraviolet spectroscopy deals with the measurement of energy absorbed when 
electrons are promoted to higher energy levels. On passing electromagnetic radiation 
in the ultraviolet and visible regions through a compound with multiple bonds, a 
portion of the radiation is normally absorbed by the compound.  The amount of 
absorption depends on the wavelength of the radiation and the structure of the 
compound.  Absorption of electromagnetic radiation in the visible and ultraviolet 
regions of the spectrum results in changes on the electronic structure of ions and 
molecules. 
Ultraviolet spectrum records the wavelength of an absorption maximum, i.e. λmax and 
the strength of the absorption, i.e. molar absorptivity (extinction                                  
co-efficient Σmax) as defined by the combined Beer-Lambert’s law. 
The ultraviolet spectrum will be divided into the following region. 
i) Far (or vacuum) ultra violet  10 – 200 nm 
ii) Near or quartz ultraviolet   200 – 380 nm 
iii) Visible region   380 – 780 nm 
The visible region corresponds to 400-800 nm and ultraviolet region to 200-400 nm. 
Instrumental modules for measuring absorption of UV radiation 
(Willard et al., 1986) 
 
 
 
 
 
 
Radiant 
source 
Wavelength 
selector 
 
Solvent Photo 
detector 
 
Sample 
Read out Device 
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Absorption Laws (Jag Mohan, 2006) 
The absorption of light by the molecules is governed by the following laws. 
a) Beer’s law 
It states that the fraction of the incident light absorbed is proportional to the 
number of the absorbing molecules in the light path and will increase concentration or 
sample thickness. 
 
b) Lambert’s law 
It states that the fraction of the monochromatic light absorbed by a 
homogeneous medium is independent of the intensity of the incident light and each 
successive unit layer absorbs an equal fraction of the light incident on it. 
From the laws, the following empirical expression, known as Beer – Lambert’s law 
Log10 ∑ ==




 Acl
I
I 0
 
Where, Io - Intensity of incident light 
  I - Intensity of emerged light 
 Σ - Molar absorptivity 
 c - Concentration of solute in moles/litre 
 l - Path length (Cm) 
 A - Absorbance 
 
Limitations of Beer-Lambert’s Law 
The Beer-Lambert law is rigorously obsessed provided a single species gives 
rise to the observed absorption.  However the law may not obsessed when, 
i) Different forms of the absorbing molecules are in equilibrium. 
ii) Solute and solvent from association complexes. 
iii) There is a thermal equilibrium between ground electronic state and 
a low lying excited state. 
iv) The compounds are charged by irradiation (fluorescent 
compounds). 
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Deviations from Beer’s Law (Sharma, B.K, 2000) 
                   According to Beer’s law, a straight line passing through the origin should 
be obtained, when a graph is plotted between absorbance (A) and concentration. 
Deviation from the law may be positive or negative, according to whether the 
resulting curve is concave upwards or concave downwards. 
The deviations from the Beer’s law may be due to interaction of the solute 
molecules with each other or with the solvent or may be due to instrumental factors. 
The most important reasons that cause deviations are 
i) Negative deviation can always be expected when the illumination is not 
monochromatic. 
ii) The presence of impurities that fluoresces or absorb at the required 
absorption wavelength. 
iii) Environmental errors such as solvent, temperature and pressure. 
iv) Chemical factors such as change in pH and chemical equilibrium, 
presence of complexing agent, competitive metal ion reactions and 
concentration dependence. 
v) Refractive index of sample. 
vi) Instrumental errors such as radiation, stability of radiation source, 
stability of slit control and electronics and reliability of the optical parts. 
 
Choice of solvent (Chatwal, 2000) 
A suitable solvent for ultraviolet spectroscopy should meet the following 
requirements. 
a) It should not itself absorb radiations in the region under investigation. 
b) It should be less polar so that it has minimum interaction with the solute              
molecules. 
c) The solvent used should be of high purity. 
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Following table gives a list of common solvents used in UV spectroscopy 
(Williams, 2007) 
 
 
Solvents 
Minimum wavelength 
for   1cm cell (nm) 
1 Acetonitrile 190 
2 Carbon tetrachloride 257 
3 Chloroform 237 
4 Cyclohexane 195 
5 Ether 215 
6 Ethanol 204 
7 Hexane 201 
8 Methanol 203 
9 Methylene dichloride 220 
10 Water 191 
 
Solvent Effects (William Kemp, 1996) 
The position and intensity of an absorption band may shift when the spectrum 
is recorded in different solvents. For changes to solvents of increased polarity we can 
summarize the normal pattern of shifts as follows. 
1. Conjugated dienes and aromatic hydrocarbons experience very little 
solvent shift. 
2. α,β unsaturated carbonyl compounds show two different shifts. 
i) The pi - pi* bond moves to longer wave length (red shift) 
ii) The n - pi* bond moves to shorter wavelength (blue shift) 
 
Wavelength Choice (Robert D Braun, 2006) 
When choosing a wavelength at which to make an absorbance measurement, 
three factors must be considered. 
Factor 1 
If the solution contains more than one absorbing species, the wavelength that 
should be choosen, whenever possible, is that at which the second species in the 
solution does not absorb radiation. 
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Factor 2 
It must be considered when a wave length is choosen is the required sensitive 
of the assay. 
Factor 3 
This factor to be considered is the sensitive of the assay to small changes in 
wavelength it is preferable to choose a wavelength at which the absorbance will not 
be significantly altered if the wavelength is slightly changed. 
 
Detectors (Sharma, B K, 2000; Willard et al., 1986) 
A detector is a transducer that convert electromagnetic radiation into an 
electron flow and subsequently, into a current flow or voltage in the readout circuit. 
Photoelectric or photo multiplier tubes are generally used as detectors. 
The detector must have the following important requirements. 
a) It must respond to radiant energy over a broad wavelength range. 
b) It should be sensitive to low levels of radiant power. 
c) It should rapidly respond to the radiation and produce an electrical signal that 
can be readily amplified. 
d) It should have relatively low noise level (for stability) 
e) The signal produced is directly proportional to the power of beam striking it. 
 
Qualitative analysis 
 The assay of an absorbing substance may be quickly carried out by preparing a 
solution in a transparent solvent and measuring its absorbance at a suitable 
wavelength. The wavelength normally selected is a wavelength of maximum 
absorption (λmax) where small errors in setting the wavelength scale have little effects 
on the measured absorbance. 
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Quantitative analysis (Beckett and Stenlake, 2002) 
Assay of Substances in single Component Samples 
 Absorption spectroscopy is one of the most useful tools available to the 
chemist for quantitative analysis. The most important characteristics of photometric 
and spectrophotometric methods are high selectivity and ease of convenience. 
Quantitative analysis (assay of an absorbing substance) can be done using following 
methods. 
- Use of A (1%, 1cm) values 
- Use of calibration graph (multiple standard methods) 
- By single or double point standardization method 
 
Use of A (1%, 1cm) values 
 This method can be used for the estimation from formulation or raw material 
when reference standard not available. The use of standard A (1%, 1cm) value avoids 
the need to prepare a standard solution of the reference substance in order to 
determine its absorption. 
 
Use of calibration graph 
 In this method a calibration curve is plotted using concentration (X-axis) Vs 
absorbance (Y-axis) with the value of 5 or more standard solutions. A straight line is 
drawn through maximum number of points. This method is called as line of best fit. 
By interpolating the absorbance of the sample solution and using the calibration 
curve, the concentration of the drug amount and percentage purity can be calculated. 
 
Single or double point standardization 
 The procedure involves the measurement of the absorbance of a sample 
solution and of a standard of the reference substance. The standard and the sample 
solution are prepared in similar manner; ideally the concentration of the standard 
solution should be close to that of the sample solution. The concentration of the 
substance in the sample is calculated using following formulas, 
Ctest = Atest / Astd × Cstd 
Where, 
Ctest and Cstd are the concentration of the sample and standard solutions, 
respectively. 
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Atest and Astd are the absorbance of the sample and standard solutions, 
respectively. 
In double point standardization, the concentration of one of the standard solution is 
greater than that of the sample while the other standard solution has a lower 
concentration than the sample solution. The concentration of the substance in the 
sample solution is given by 
(Atest – Astd1)(Cstd1-Cstd2) +Cstd1 (Astd1-Astd2) 
Ctest= 
Astd1-Astd2 
Where, 
Cstd is the concentration of the standard solution. 
Atest and Astd are the absorbance of the sample and standard solutions, 
respectively. 
Std 1 and Std 2 are the more concentrated standard and less concentrated 
standard solutions, respectively. 
 
Assay of Substances in Multi Component Samples 
 The spectrophotometry assay of drugs rarely involves the measurement of 
absorbance of samples containing only one absorbing component. The pharmaceutical 
analyst frequently encounters the situation where the concentration of one or more 
substances is required in samples known to contain other absorbing substances which 
potentially interfere in the assay. Unwanted absorption from these sources is termed 
irrelevant absorption and if not removed, imparts systematic errors to the assay of the 
drug in the sample. A number of modifications to the simple spectrophotometric 
procedure for single-component samples are available to the analyst, which may 
eliminate certain sources of interferences and permit the accurate determination of 
one or all of the absorbing components. 
The basis of all the spectrophotometric technique for multi-component 
samples is the property that at all wavelengths: 
a) The absorbance of a solution is the sum of absorbance of the individual 
components. 
b) The measured absorbance is the difference between the total 
absorbance of the solution in the sample cell and that of the solution in 
the reference (blank) cell. 
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The determination of the multi-component samples can be done by using the 
following methods. 
o Assay of a single-component sample 
o Assay using Absorbance corrected for interference 
o Assay after solvent extraction of the sample 
o Simultaneous equation method 
o Absorbance ratio method (Q-Analysis) 
o Geometric correction method 
o Orthogonal Polynomial Method 
o Difference Spectrophotometry 
o Derivative Spectrophotometry and 
o Chemical derivatisation 
 
Simultaneous equation method 
If a sample contains two absorbing drugs (X and Y) each of this absorbs at the 
λmax of the other. It may be possible to determine both drugs by the technique of 
simultaneous equation (Vierodt’s method). 
The Informations required are as follows, 
a) The absorptivities of X at λ1 and λ2, ax1 and ax2, respectively 
b) The absorptivities of Y at λ1 and λ2, ay1 and ay2, respectively 
c) The absorbance of the diluted sample at λ1 and λ2, A1 and A2 respectively. 
Let Cx and Cy, be the concentrations of X and Y respectively in the diluted sample. 
Two equations are constructed based upon the fact that at λ1 and λ2, the 
absorbance of the mixture is the sum of the individual absorbances of x and y, 
At λ1  A1 = ax1bcx + ay1bcy  ----------- (1) 
At λ2  A2 = ax2bcx + ay2bcy  ----------- (2) 
For measurements in 1 cm cells, b=1.  Rearrange eq. (2) 
2
22
y
xx
y
a
caA
c
−
=  
Substituting for cy in eq. (1) and rearranging gives 
21
112
12
2
yxyx
yy
x
aaaa
aAaA
c
−
−
=  (3) 
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21
22
12
12
yxyx
xx
y
aaaa
aAaA
c
−
−
=  (4) 
 
Absorbance ratio method 
The absorbance ratio method is a modification of the simultaneous equation 
procedure. It depends on the property that, for a substance which obeys Beer’s law at 
all wavelengths, the ratio of absorbance at any two wavelengths is a constant value 
independent of concentration or path length. For example, two different dilutions of 
the same substance give the same absorbance ratio A1/A2, 2.0. In the USP, this ratio is 
referred to as a Q value. The British Pharmacopoeia also uses a ratio of absorbance at 
specified wavelengths in certain confirmatory tests of identity. For example, 
Cyanocobalamine exhibits three λmax at 278 nm, 361 nm and 550 nm. The A360/A550 is 
required to be 3.30 ± 0.15 and the A361/A278 to be 1.79 ± 0.09. 
 
Geometric correction method 
A number of mathematical correction procedures have been developed which 
reduce or eliminate the background irrelevant absorption that may be present in 
samples of biological origin. The simplest of these procedures is the three-point 
geometric procedure, which may be applied if the irrelevant absorption is linear at the 
three wavelengths selected. 
 
Orthogonal polynomial method 
The technique of orthogonal polynomials (Glenn, 1963) is another 
mathematical correction procedure which involves more complex calculations than 
the three –point correction procedure. The basis of the method is that an absorption 
spectrum may be represented in terms of orthogonal functions as follows: 
A (λ) = p0P0(λ) + p1P1(λ) + p2P2(λ) . . . pnPn(λ) 
Where A denotes the absorbance at wavelength λ belonging to a set of n + 1 equally 
spaced wavelengths at which the orthogonal polynomials, P0 (λ), P1 (λ), P2 (λ) . . . Pn 
(λ) are each defined. 
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Area under the curve method 
From the spectra obtained for calculating the simultaneous equation, the area 
under the curve were selected at a particular wavelength range for both the drugs were 
each drug  have its absorption. The “X” values of the drugs were determined at the 
selected AUC range. The “X” value is the ratio of area under the curve at the selected 
wavelength range with the concentration of the component in mg/ml. These “X” 
values were the mean of six independent determinations. A set of two simultaneous 
equations were obtained by using mean “X” values. And further calculations are 
carried out to obtain the concentration of each drug present in the sample. 
 
Derivative spectrophotometry 
Derivative spectrophotometry involves the conversion of a normal spectrum to 
its first, second or higher derivative spectrum. The transformations that occur in the 
derivative spectra are understood by reference to a Gaussian band which represents an 
ideal absorption band. In the context of derivative spectrophotometry, the normal 
absorption spectrum is referred to as the fundamental, zero order or D° spectrum. The 
first derivative (D1) spectrum is a plot of the ratio of change of absorbance with 
wavelength against wavelength. 
These spectral transformations confer two principle advantages on derivative 
spectrophotometry. Firstly, an even order spectrum is of narrower spectral bandwidth 
than its fundamental spectrum. A derivative spectrum therefore shows better 
resolution of overlapping bands than the fundamental spectrum and may permit the 
accurate determination of the λmax of the individual bands. Secondly, derivative 
spectrophotometry discriminates in favour of substances of narrow spectral bandwidth 
against broad bandwidth substances. This is because ‘the derivative amplitude (D), 
i.e. the distance from a maximum to a minimum, is inversely proportional to the 
fundamental spectral bandwidth (W) raised to the power (n) of the derivative order. 
Thus,         D α (1/W)n 
All the amplitudes in the derivative spectrum are proportional to the concentration of 
the analyte, provided that Beer’s Law is obeyed by the fundamental spectrum. The 
measured value in a quantitative assay is the largest amplitude that is unaffected by 
the presence of other, absorbing components of the sample. 
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Difference spectrophotometry 
The selectivity, accuracy of spectrophotometric analysis of samples containing 
absorbing interferences may be markedly improved by the technique of difference 
spectrophotometry. The essential future of a difference spectrophotometric assay is 
that the measured value is the difference absorbance (A) between two equimolar 
solutions of the analyte in different chemical forms which exhibit difference spectral 
characteristics. The criteria for applying difference spectrophotometry to the assay of 
a substance in the presence of other absorbing substances are that, 
 Reproducible changes may be induced in the spectrum of the analyte by the 
addition of one or more reagents. 
 The absorbance of the interfering substances is not altered by the reagents. 
 
The simplest and most commonly employed technique for altering the spectral 
properties of the analyte is the adjustment of the pH by means of aqueous solutions of 
acid, alkali or buffers. The ultra violet visible absorption spectra of many substances 
containing ionisable functional groups, e.g. phenols, aromatic carboxylic acids and 
amines are dependent on the state of ionization of the functional groups and 
consequently on the pH of the solution. The measured value in a quantitative 
difference spectrophotometric assay is the ∆A at any suitable wavelength measured to 
the baseline, e.g.  ∆A1 at λ1 or amplitude between an adjacent maximum and 
minimum, 
e.g.  ∆A2 at λ2 and λ1 
∆A =AALK-AACID 
Where Aalk and Aacid are the individual absorbances at λ1 in 0.1M sodium 
hydroxide and 0.1M hydrochloric acid solution, respectively. 
∆ A=   ∆ abc 
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1.3 CHROMATOGRAPHY (Gary D. Christian, 2005; Willard et al., 1986) 
Chromatography is a physical method of separation in which the components 
to be separated are distributed between two phases, one of which is stationary 
(stationary phase), while the other (the mobile phase) moves in a definite direction. 
Chromatography was invented and named by the Russian Botanist Mikhail Tswett at 
the beginning of the 20th Century. 
 
1.3.1 Methods in Chromatography (Sethi, 2001; Mendham et al., 2002) 
1. Absorption Chromatography 
• Normal Phase Chromatography 
• Reversed Phase Chromatography 
• Ion exchange Chromatography 
• Affinity Chromatography 
• Hydrophobic Interaction Chromatography (HIC) 
2. Partition Chromatography 
• Gas Chromatography 
• Liquid -Liquid Partition Chromatography 
3. Size Exclusion Chromatography (SEC) 
• Gel permeation Chromatography 
• Gel Filtration Chromatography 
 
Normal Phase Chromatography 
The term normal phase Chromatography is used when the stationary phase is 
polar and the mobile phase is non-polar.  In this case the solute elution order is based 
on the principle that non-polar solutes prefer the mobile phase and elute earlier, 
whereas polar solutes prefer the stationery phase and elute later. 
 
Reverse Phase Chromatography 
In Reverse phase chromatography (RPC) the stationary phase is non-polar and 
the mobile phase is polar, the solute elution order is commonly the reverse of that 
observed in normal phase chromatography, i.e. polar compounds elute earlier and non 
polar compounds elute later. 
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1.3.2 High Performance Liquid Chromatography (Francis Rouessac, 2000) 
High performance liquid chromatography (HPLC) is an analytical technique in 
general use.  It evolved from preparative column chromatography and its performance 
(efficiency, resolution) has been greatly enhanced by the use of elaborate stationary 
phases composed of spherical particles with diameter ranges between 2 and 5 µm.  
However, because the particles are small, the head pressure needed to force the 
mobile phase through the column packing must be greatly increased compared to that 
used in preparative liquid chromatography.  Because of this, the letter P in HPLC has 
occasionally corresponded to the word ‘pressure’. 
 
High performance liquid chromatography (HPLC) is the most versatile and widely 
used type of elution chromatography.  The technique is used by chemists to separate 
and determine species in a variety of organic, Inorganic and biological materials. 
 
1.3.3 RP-HPLC (Mendham et al., 2002) 
High performance systems have meant that liquid chromatography has over 
taken gas chromatography as HPLC now provide the following features, 
1. High Resolving Power 
2. Speedy separation 
3. Continuous monitoring of the column effluent 
4. Accurate quantitative measurement 
5. Repetitive and reproducible analysis using some columns 
6. Automation of the Analytical procedure and data handling 
 
1.3.4 Mobile Phase 
A successful chromatographic separation depends upon differences in the 
interaction of the solutes with the mobile phase and the stationary phase. In liquid 
chromatography, the choice and variation of the mobile phase is of critical importance 
in achieving optimum efficiency.  HPLC grade solvents tend to be costly.  To ensure 
consistent performance, the solvent should not contain any trace amounts of other 
materials, including water for organic solvents. 
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1.3.5 Pumping Systems (Douglas et al., 2006; Willard et al., 1986) 
The requirements for liquid chromatographic pumps include 
• Ability to generate pressures of up to 6000 psi (Ibs/in2) 
• Pulse free output 
• Flow rate ranging from 0.1 to 10 ml/min 
• Flow reproducibility of 0.5% relative or better 
• Resistance of corrosion by a variety of solvents 
Types of pumps 
• Reciprocating Piston Pumps 
• Syringe Type Pump 
• Constant Pressure Pump 
 
1.3.6 Columns for HPLC (Willard et al., 1986) 
The columns most commonly used are made from precision bore polished 
stainless steel tubing; typical dimensions are 10-30 cm long and 4 (or) 5 mm internal 
diameter.  The stationary phase (or) packing is retained at each end by thin stainless 
steel frits with a mesh of 2 µm or less. The packing used in modern HPLC consist of 
small, rigid particles having a narrow particles size distribution. The types of column 
used in HPLC are 
• Standard columns 
• Radial compression columns 
• Narrow Bore columns 
• Short, fast columns 
• Guard columns and In-line filters 
 
1.3.7 Temperature Control 
Separation columns should be housed within a stable system with temperature 
variations of less than 0.1°C, the temperature changes must be avoided. Circulating 
air bath or electrically heated chambers are used to control the column temperature. 
The solvent is preheated separately before entering the separation column. 
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1.3.8 Detectors (Ashutoshkar, 2005) 
The main function of the detector in HPLC is to monitor the mobile phase 
coming out the column, which in turn emits electrical signals that are directly 
proportional to the characteristics either of the solute or the mobile phase.  
 
1.3.9 Applications of RP-HPLC 
Chromatography has grown to be the premier method for separating closely 
related chemical species.  In addition, it can be employed for qualitative identification 
and quantitative determination of separated species. 
1.3.9.1 Qualitative analysis (Douglas et al., 2006) 
A chromatogram provides only a single piece at qualitative information about 
each species in a sample, namely, its retention time or its position on the stationary 
phase after a certain elution period.  Additional data can of course be derived from 
chromatograms involving different mobile phases and stationary phases and various 
elution temperatures.  Still the amount of information obtainable by chromatography 
is small compared with the amount provided by a single IR, NMR or mass spectrum.  
Further more spectral wavelength or frequency data can be determined with much 
higher precision than can their chromatographic counter part (tR).   It is important to 
note that the chromatograms may not lead to positive identification of species present 
in a sample, but they often provide sure evidence of the absorbance of certain 
compounds.  If the sample does not produce a peak at the same retention time as a 
standard run under identical conditions, it can be assumed that the compound is absent 
(or is present at a concentration level below the detection unit of the procedure). 
 
1.3.9.2 Quantitative analysis (Lloyd R. Snyder et al., 1997) 
Quantitative chromatography is based upon a comparison of either the height 
or the area of the analyte peak, with that of one or more standards.  The different 
calibration methods are given as the following 
Normalized Peak Area 
After completion of a run and the integration of all significant peaks in the 
chromatogram, the total peak area can then be calculated.  The area present of any 
individual peak is referred to as the normalized peak area. 
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External Standard Calibration 
Determination of the concentration of an unknown sample by constructing a 
calibration plot using external standards. Standard solutions (some times called 
calibrators) are prepared at known concentrations. A fixed volume of each standard 
solution is injected and analyzed and the peak responses are plotted vs. concentration. 
The calibrators are referred to as external standard. Concentration is determined 
graphically from a calibration plot, or numerically using response factors. 
 
Internal Standard Calibration 
In this technique for calibration involves the addition of an internal standard to 
the calibration solutions and samples.  The internal standard is a different compound 
from the analyte. 
The main use of internal standard is it can compensate for changes in sample 
size or it can compensate for changes in concentration due to instrumental variations 
or certain samples require significant pretreatment, E.g. filtration, extraction etc., 
which results in sample loss. So the internal standard is added prior to sample 
preparation to correct for sample loss.  A calibration plot is produced by preparing 
and analyzing calibration solutions containing different concentration of the internal 
standard added. The peak area ratio of standard and internal standard added vs. 
standard concentrations. The plot can be used directly to determine the concentration 
of sample using slope and intercept. 
 
Method of Standard Addition 
Different weights of analyte are added to the sample matrix, which initially 
contains an unknown concentration of the analyte.  Extrapolation of a plot response 
found for the standard addition calibration concentrations to zero concentration 
defines the original concentration in the un-spiked sample. 
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1.4 ANALYTICAL METHOD VALIDATION 
(Code Q2A; Q2B, ICH Guidelines - 1994 and 1996; USP 1995) 
Method validation is the process to confirm that the analytical procedure employed 
for a specific test is suitable for its intended use.  Methods need to be validated or 
revalidated, 
 Before their introduction into routine use 
 Whenever the conditions change for which the method has been validated   
e.g., instruments with different characteristics. 
 Whenever the method is changed, and the change is outside the original scope 
of the method.  
 The International Conference on Harmonization (ICH) of Technical 
Requirements for the Registration of Pharmaceutical for human use has 
developed a consensus text on the validation of analytical procedures. The 
document includes definitions for different validation characteristics. 
 
VALIDATION FOR UV-VISIBLE SPECTROSCOPY METHOD- USP 
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VALIDATION FOR HPLC METHOD – ICH GUIDELINE 
 
1.4.1. Specificity 
 Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. Lack of specificity of an individual 
analytical procedure may be compensated by other supporting analytical procedures. 
An investigation of specificity should be conducted during the validation of 
identification tests, the determination of impurities and the assay.  The procedures 
used to demonstrate specificity will depend on the intended objective of the analytical 
procedure. 
 
1.4.2. Accuracy 
The accuracy of an analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or on an 
accepted reference value and the value found. 
 
1.4.2.1. Assay 
- Assay of Active Substance 
- Assay of Medicinal products       
 several methods are available to determine the accuracy. 
a. Application of an analytical procedure to an analyte of known purity (e.g. 
reference material). 
b. Comparison of the results of the proposed analytical procedure with those 
of a second well-characterized procedure, the accuracy of which is stated 
and/or defined (independent procedure). 
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c. Application of the analytical procedure to synthetic mixtures of the 
product components to which known quantities of the substance to be 
analyzed have been added. 
 
1.4.2.2. Impurity (Quantification) 
Accuracy should be assessed on sample (substance /products) spiked with 
known amounts of impurities.  It should be clear how the individual or total impurities 
are to be determined. 
 
1.4.3. Precision 
The precision of an analytical procedure expresses the closeness of agreement 
between a series of measurement obtained from multiple sampling of the same 
homogenous sample under the prescribed conditions. Precision of an analytical 
procedure is usually expressed at the variance, standard deviation or coefficient of 
variation of a series of measurements. Validation of tests for assay and for 
quantitative determination of impurities includes an investigation of precision. 
 
1.4.3.1. Repeatability 
Express the precision under the same operating conditions over a short interval 
of time.  Repeatability is also termed as intra - assay precision. It should be assessed 
using a minimum of nine determinations covering the specified range for the 
procedure (e.g. three concentration/three replicates each) or a minimum of 
determinations at 100% of the test concentration. 
 
1.4.3.2. Intermediate Precision 
The extent to which intermediate precision should be established depends on 
the circumstances under which the procedure is intended to be used.  The applicant 
should establish the effects of random events on the precision of the analytical 
procedure. Typical variations to be studied include days, analysts, equipments, etc. 
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1.4.3.3. Reproducibility 
Reproducibility is assessed by means of an inter-laboratory trial.  
Reproducibility should be considered in case of the standardization of an analytical 
procedure, for instance inclusion of procedures in Pharmacopoeias. 
 
1.4.4. Linearity 
Linearity of an analytical procedure is its ability (with in a given range) to 
obtain test results which are directly proportional to the concentration (amount) of 
analyte in the sample. 
Linearity should be evaluated by visual inspection of a plot of signals as a 
function of analyte concentration or content.  If there is a linear relationship, test 
results should be evaluated by appropriate statistical methods.  For example, 
calculation of a regression line by the method of least square.  Therefore data from 
regression line itself may be helpful to provide mathematical estimates of the degree 
of linearity. 
 
1.4.5. Range 
Range of an analytical procedure is the interval between the upper and lower 
concentration (amounts) of analyte in the sample including these concentrations for 
which it has been demonstrated that the analytical procedure has a suitable level of 
precision, accuracy and linearity. 
The following minimum specified ranges should be considered 
- For the assay of an active substance or a finished product normally from 
80-120 % of the test concentration. 
- For the content uniformity, covering a minimum of 70-130 % of the test 
concentration. 
- For dissolution testing, 20% over the specified range (e.g.), If the 
specifications for a controlled release product cover a region from 20% 
after 1hour, up to 90% after 24 hours, the validated range would be           
0-110% of label claim. 
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1.4.6. Limit of Detection 
The Detection Limit is determined by the analysis of samples with known 
concentration of analyte and by establishing that minimum level at which the analyte 
can reliably detected. 
 
1.4.6.1. Based on visual evaluation 
Visual evaluation may be used for non-instrumental methods but may be used 
with instrumental methods. 
 
1.4.6.2. Based on signal-to-noise ratio 
Determination of the signal-to-noise ratio is performed by comparing 
measured signals from samples with known low concentrations of analyte with those 
of blank samples and establishing the minimum concentration at which the analyte 
can be reliably detected. A signal-to-noise ratio 3 or 2:1 is generally considered 
acceptable for estimating the detection limit. 
 
1.4.6.3. Based on the standard deviation of the response and the slope 
 The Detection Limit (DL) may be expressed as 
    DL = 3.3σ/S 
 Where, 
   σ = The standard deviation of the response 
   S = The slope of the calibration curve 
 The slope, S may be estimated from the calibration curve of the analyte. 
The estimate of σ may be carried out in a variety of ways. 
 
1.4.6.3.1. Based on the Standard Deviation of the Blank 
 Measurement of the magnitude of analytical background response is 
performed by analyzing an appropriate number of blank samples and calculating the 
standard deviation of these responses. 
 
1.4.6.3.2. Based on the calibration curve 
 A specific calibration curve should be studied using samples containing an 
analyte in the range of DL. The residual standard deviation of a regression line or the 
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standard deviation of y-intercept of regression lines may be used as the standard 
deviation. 
 
1.4.7. Limit of Quantification 
The quantification limit is generally determined by the analysis of samples 
with known concentrations of analyte and by establishing the minimum level at which 
the analyte can be quantified with acceptable accuracy and precision. 
 
1.4.7.1. Based on visual evaluation 
Visual evaluation may be used for non-instrumental methods but may also be 
used with instrumental methods. 
 
1.4.7.2. Based on Signal- to-Noise ratio 
Determination of the Signal-to-Noise ratio is performed by comparing 
measured signals from samples with known low concentrations of analyte with those 
of blank samples and by establishing the minimum concentration at which the analyte 
can be reliably quantified. A typical Signal- to-Noise ratio is 10:1. 
 
1.4.7.3. Based on the Standard Deviation of the Response and the slope 
The Quantification Limit (QL) may be expressed as 
S
10σQL =  
Where, 
σ = The standard deviation of the response 
S = The slope of the calibration curve 
The slope S may be estimated from the calibration curve of the analyte.  
 
1.4.7.3.1. Based on standard deviation of the blank 
Measurement of the magnitude of analytical background response is 
performed by an appropriate number of blank samples and calculating the standard 
deviation of these responses. 
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1.4.7.3.2. Based on the Calibration Curve 
A specific calibration curve should be studied using samples containing an 
analyte in the range of QL. The residual standard deviation of a regression line or the 
standard deviation of y-intercepts of regression lines may be used as the standard 
deviation. 
 
1.4.8. Robustness 
The evaluation of robustness should be considered during the development 
phase and it depends on the type of procedure under study.  It should show the 
reliability of an analysis with respect to deliberate variations in method parameters. 
Incase of liquid chromatography, examples of typical variations are 
- Influence of variation of pH in a mobile phase 
- Influence of variations in mobile phase composition 
- Different columns (different lots and / or suppliers) 
- Temperature 
- Flow rate 
In the case of gas-chromatography, examples of typical variations are 
- Different columns (different lots and / or suppliers) 
- Temperature 
- Flow rate 
 
1.4.9 Ruggedness 
 The United States pharmacopoeia (USP) define ruggedness as the degree of 
reproducibility of test results obtained by the analysis of the same samples under a 
variety of normal test conditions such as different labs, different analysts, different 
lots of reagents etc.  Ruggedness is a measure of reproducibility of test results under 
normal expected operational conditions from laboratory to laboratory and from 
analyst to analyst. 
 
1.5 SYSTEM SUITABILITY PARAMETERS 
(Anonymous, USP XXIII 1995; Beckett and Stenlake, 2002; Willard et al., 1986) 
The requirements for system suitability are usually developed after method 
development and validation have been completed.  The criteria selected will be based 
on the actual performance of the method as determined during its validation. The 
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following parameters that can be used to determine system suitability prior to 
analysis. 
 
1) Retention Time 
Chromatographic retention is to measure the time between the injection point 
and maximum of the detector response for correspondent compound.  This parameter 
called “retention time” (tR).   Retention time, tR is inversely proportional to the eluent 
flow rate. 
 
2) Resolution 
The degree of separation or resolution of two adjacent bands is defined 
as the distance between band peaks (or centers) divided by the average band 
width and bandwidths are measured in units of time. 
Rs = 
tR2 – tR1 
0.5 (w2 + w1) 
 
3) Theoretical Plates 
A column may be considered as being made up of a large number of 
theoretical plates where distribution of sample between stationary and mobile phase 
occurs. The number of Theoretical plates (n) in a column is given by the relationship: 
n =      5.54(tR / w1/2)2 
          Where, 
           tR       =   retention time of substance   
            W1/2 = width of the peak at half height, obtained directly by electronic 
integrators 
              The value of ‘n’ depends upon the substance being chromatographed 
as well as the operating conditions such as mobile phase, temperature etc. 
Limit = n > 2000 is desirable. 
 
4) Height Equivalent to a Theoretical plate (HETP) 
 A theoretical plate can be of any height, which decides the efficiency of 
separation.  If HETP is less, the column is more efficient.  If HETP is more, the 
column is less efficient.  The height equivalent to a theoretical plate (HETP) is given 
by 
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HETP = 
Length of column 
           N 
                    Where, 
                                 n = No. of theoretical plates 
 
 
 
5) Capacity Factor (K') 
It is the measure of a sample peak in the chromatogram being specific for a 
given compound, a parameter which specifies the delay of a substance to be 
separated. 
K' = 
t r - to 
to 
Where 
tr     = retention time measured from time of injection to time of elution       
of     peak maximum 
to       = void volume 
Generally the value of K' is > 2 
 
5) Peak Asymmetry 
If k′ is higher at low concentrations a situation often prevailing in adsorption 
chromatography, the low concentration wings of bands will move more slowly than 
the high concentration parts, and as an initially symmetric band moves down the 
column it will become skewed and eventually tailed.  The result is a band with a sharp 
front and a long, more or less exponential tail.  Asymmetrical peaks can also result 
from extra column effects, particularly injection problems.  In fact, peak symmetry 
can be used as a criterion of column performance.  A very simple comparison of the 
back half width, b, of the peak at 10% of the peak height, divided by the 
corresponding front half-width, a, gives the asymmetry factor : 
AF = 
b 
a 
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6) Tailing Factor (T) 
The tailing factor T, a measure of peak symmetry, is unity for perfectly 
symmetrical peaks and its value increases as tailing becomes more pronounced. In 
some cases, values less than unity may be observed. As peak asymmetry increases, 
integration, and hence precision becomes less reliable. 
 
T = 
W 0.05 
2f 
 
Where, 
W0.05 = width of peak at 5% height 
f = Distance from the peak maximum to the leading edge of the peak, the 
distance being measured at a point 5% of the peak height from the baseline. 
Limit: ≤ 2 is preferable. 
 
1.6 STATISTICAL PARAMETERS 
Linear regression (Mendham et al., 2002) 
Once a linear relationship has been shown to have a high probability by the 
value of the correlation coefficient ‘r’, then the best straight line through the data 
points has to be estimated. This can often be done by visual inspection of the 
calibration graph, but in many cases it is far more sensible to evaluate the best straight 
line by linear regression (the method of least squares). 
The equation of straight line is 
y = mx + c 
Where, y the dependent variable is plotted as result of changing x, the independent 
variable. 
To obtain the regression line ‘y on x’ the slope ‘m’ of the line and the intercept ‘c’ on 
the y axis are given by the following equation. 
m  = 
N Σxy – (Σx) (Σy) 
N Σx2 – (Σx)2 
and 
c = 
(Σy) (Σx2) – (Σx) (Σxy) 
N Σx2 – (Σx)2 
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Correlation co-efficient (Gary D Christian, 2005) 
The correlation co-efficient is used as a measure of the correlation between 
two variables.  When variables x and y are correlated rather than being functionally 
related. The Pearson correlation co efficient is one of the most convenient to 
calculate. This is given by, 
 
r = 
n Σx1y1 - Σx1y1 
{[n Σx12 – (Σx1)2] [n Σy12 – (Σy1)2]}1/2 
 
Where n is the number of data points. 
The maximum value of r is 1.  When this occurs, there is exact correlation between 
the two variables.  When r is zero, there is complete independence of the variables.  
The minimum value of r is -1.  A negative correlation co-efficient indicates that the 
assumed dependence is opposite to what exists and is therefore a positive co-efficient 
for the revered relation.  The fit must be quite poor before r becomes smaller than 
about 0.98 and is really very poor when less then 0.9. 
Standard deviation (Underwood, 2006) 
It is commonly used in statistics as a measure of precision and is more 
meaningful than is the average deviation. It may be thought of as a root-mean-square 
deviation of values from their average and is expressed mathematically as 
( )
1N
xx
S
ni
1i
i
−
−
=
∑
=
=
 
Where, 
S     =   Standard deviation 
If N is large (50 or more) then of course it is immaterial whether the term in 
the denomination is N -1 or N 
Σ  = Sum 
x  = Mean or arithmetic average 
x - x i  = Deviation of a value from the mean 
N = Number of observations 
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Percentage relative standard deviation (% RSD) 
It is also known as coefficient of variation (CV). It is defined as the standard 
deviation (S.D) expressed as the percentage of mean. 
C 100
x
S.DRSD  %or  V ×=  
Where, 
S.D = Standard deviation 
x  = Mean or arithmetic average 
The variance is defined as S2 and is more important in statistics than S itself.  
However, the latter is much more commonly used with chemical data. 
 
Standard error of mean (S.E) 
 Standard error of mean can be defined as the value obtained by division of 
standard deviation by square root of number of observations. It is mathematically 
expressed as, 
n
S.D.S.E. =  
Where, 
S.D = Standard deviation 
n = number of observations 
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2. LITERATURE REVIEW 
 
 
2.1 DRUG PROFILE 
 
 
TORSEMIDE (THE MERCK INDEX, 2006) 
 
 Structure 
 
 
 
 Molecular Formula 
              C16 H20 N4 O3 S 
 
 Chemical Name 
  N-[(isopropyl amino) carbonyl]-4-[(3-methyl phenyl) amino] pyridine-3-
sulfonamide 
 
 Molecular Weight   
            348.241 g / mol 
 
 Protein binding                     
 Highly bound (>99%) 
 
 Half life                                         
 3.5 hours 
 
 Routes  
 Oral, IV 
 
 Category  
 
Torsemide is a pyridine-sulfonylurea type loop Diuretic mainly used in the 
management of oedema associated with congestive heart failure. It is also used at low 
doses for the management of hypertension. 
 
 Description   
 White to off white powder 
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 Storage  
Stored in tightly closed container 
 
 Pharmacological action 
 
Torsemide is a new loop diuretic that potentially may have renal tubular 
effects from both the blood and urinary sides of the nephron. 
 
Side effects 
 
Torsemide can cause orthostatic hypotension, gastro intestinal disturbances, 
muscle cramps, skin rashes, dizziness, tiredness, and headache. All side effects 
usually are mild and transient.  
Melting point 
 163-164·c 
 
SPIRONOLACTONE (THE MERCK INDEX, 2006)  
 
 Structure 
 
 
 
 
 
Molecular formula                        
 C14 H32 O4 S 
 
Chemical Name 
 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21, 17-carbolactone 
 
Molecular weight  
 416.574 g /mol 
 
 
Half life                     
              10 minutes 
 
Routes                 
              Oral 
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Category                                
              Loop diuretic 
 
Description            
              Fine white powder 
 
Storage                   
              Well closed tight container 
 
Mechanism of action   
 
Spironolactone inhibits the effects of aldosterone by Competing for 
intracellular aldosterone receptors in the distal tubule cells. 
 
Adverse effects                      
Spironolactone is associated with an increased risk bleeding from the stomach 
and duodenum, but a causal relationship between the two has not been established. 
Because it also affects androgen receptor  and other steroid receptors. 
Identification test  
               Shake about 10 mg with 2 ml of sulphuric acid (50%); an orange solution 
with an intense yellowish fluorescence is produced. Heat the solution gently; the 
colour becomes deep red and hydrogen sulphide is evolved which turns litmus paper 
blue. Add the solution to 10 ml of water; a greenish yellow solution is produced 
which shows opalescence or a precipitate. 
Specific optical rotation:  
               Between –33o and –37o, determined in a 1% w/v solution in chloroform. 
Loss on drying 
  Not more than 0.5%, determined on 1 g by drying in an oven at 105o for 3 
hours. 
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2.2 REPORTED METHODS 
 
1. Dunn C J et al., (1995) 
 
Torsemide is a pyridine- sulfonylurea type loop diuretic. Compared to other 
loop diuretics, Torsemide has a more prolonged diuretic effect equipotent to the 
dose of furosemide and relatively decreased potassium loss. There is no evidence 
of Torsemide – induced ototoxicity demonstrated in humans. 
 
2. Melissa young et al., (2001) 
 
Torsemide is a loop diuretic used for the treatment of hypertension and for 
oedema in chronic heart failure (CHF), renal failure and cirrhosis. 
 
 
3. Senzaki H. et al., (2008) 
 
To examine the efficacy and safety of Torsemide in children with chronic 
heart failure. Torsemide can be safely used and appears to be effective for 
treatment of HF in children. Future clinical trials are warranted to verify the 
present results.  
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3. AIM AND PLAN OF WORK 
 
 
AIM OF WORK 
 
The prime importance of drug analysis is to gain information about the 
qualitative and quantitative composition of substance and chemical species, that is to 
find out what a substance is composed of and exactly how much.  
 
 This information guides development of the manufacturing operations and 
therapeutic action of drugs.  
 
Standard analytical procedure for newer drugs or formulation may not be 
available in pharmacopoeias. Hence it is essential to develop newer analytical 
methods which are accurate, precise, specific, linear, simple and rapid. 
 
Torsemide and Spironolactone is a newer combination. It has been launched in 
the market recently. 
 
Hence the present study aims to develop simple, precise and accurate methods 
for the determination of Torsemide and Spironolactone by simple UV methods and 
RP-HPLC method in bulk and in formulation. 
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PLAN OF WORK 
 The extensive survey of literature for Torsemide and Spironolactone regarding 
their physio chemical properties, pharmacological properties and analytical 
methods. This formed the basis for the development of methods. 
 Identification, selection and collection of Torsemide and Spironolactone for 
analysis. 
 Selection of suitable solvent for quantitative extraction of drug present in the 
formulations. The solvent should be readily available, economical and of 
analytical grade for UV-spectroscopy and HPLC grade for RP-HPLC and 
should not chemically interact with the compound of interest and its structural 
characteristics. 
 Selection of suitable method for analysis depending upon the spectral 
characteristics of the drug. 
 Selection of suitable wavelength for rapid and accurate                                
simple UV spectroscopic methods development. 
 Development of rapid and accurate RP-HPLC method by using UV detector. 
 Analysis of marketed tablet formulation by the proposed methods. 
 Statistical analysis of developed analytical methods. 
 Validation of analytical methods as per the ICH guidelines. 
 
 
  
 
 
 
 
 
  Materials  
      And 
   Methods
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4. MATERIALS AND METHODS 
 
4.1 MATERIALS 
 
4.1.1 Drug Sample 
 
Torsemide and Spironolactone as working standard was obtained as a gift 
sample from Dr. Reddy’s Laboratories, Hyderabad. 
 
4.1.2 Formulations Used 
TORLACTONE (Sun Pharmaceuticals Ltd., Mumbai) and DYTOR+ (Cipla 
Ltd) containing the formulation was procured from the local market. 
 
4.1.3 Chemicals and Solvents used 
All the following chemicals used were of analytical and HPLC grade. 
1. 0.1 N HCl 
2. Methanol 
3. Distilled water 
4. Acetonitrile (HPLC grade) 
4. Water for HPLC 
5. Potassium Dihydrogen phosphate 
6. Ortho phosphoric acid 
Chemicals and solvents are procured from Qualigens India Pvt. Limited and 
Loba Chemie India Limited. 
4.1.4 Instruments Used 
Instruments employed for the study were, 
• SHIMADZU AUX - 220  Digital Balance 
• SHIMADZU – 1700 Double Beam - UV – Visible spectrophotometer 
with pair of 10 mm matched quartz cells. 
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• SHIMADZU HPLC 
- SPD – IO AVP UV – VIS detector 
                       - LC – 10 ATVP solvent delivery module 
• ELICO SL 159 Spectrophotometer 
• ELICO pH meter (Model LI - 120) 
• Melting point apparatus 
4.1.5 Instruments Specifications 
A) Shimadzu AUX – 220 digital balance: (Shimadzu instruction manual) 
Specifications 
Weighing capacity 200 gms 
Minimum display 0.1 mg 
Standard deviation ≤ 0.1 mg 
Operation temperature range 5 to 40° C 
B) Shimadzu UV – Visible spectrophotometer: (Shimadzu instruction manual) 
Model : Shimadzu, UV-1700; Cuvetts: 1 Cm quartz cells. 
Specifications 
Light source 
20 W halogen lamp, Deuterium lamp. 
Light source position automatic adjustment mechanism. 
Monochromator Aberration-correcting concave holographic grating 
Detector Silicon Photodiode 
Stray Light 
0.04% or less (220 nm: NaI 10 g/l) 
0.04% or less (340 nm: NaNo2 50 g/l) 
Measurement wavelength  
range 
190~1100 nm 
Spectral Band Width 1 nm or less (190 to 900 nm) 
Wavelength Accuracy ± 0.5 nm automatic wavelength calibration mechanism 
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Recording range 
Absorbance : -3.99~3.99 Abs 
Transmittance : -399~399% 
Photometric Accuracy ± 0.004 Abs (at 1.0 Abs), ±0.002 Abs (at 0.5 Abs) 
Operating 
Temperature/Humidity 
Temperature range : 15 to 35°C 
Humidity range : 35 to 80% (15 to below 30° C) 
35 to 70% (30 to 35° C) 
 
C) Shimadzu High Performance Liquid Chromatography: (Shimadzu instruction manual) 
Detector Specifications 
Light source Deuterium Arc lamp 
Measurement wavelength range 190 to 700 nm 
Spectral Band Width 5 nm 
Wavelength Accuracy ± 1 nm 
Cell path length 10 nm 
Cell volume 20 µl 
Operating temperature range 4 to 35° C (39 to 104° F) 
Recording range 0.0001 to 4.000 AUFS 
Operating temperature/Humidity 4 to 35° C / 75 % 
Pump Specifications 
Pump type Double reciprocating plunger pump 
Pumping method Constant flow delivery and constant pressure delivery 
Suction filter 45 µm 
Line filter 5 µm mesh 
Operating temperature 4 to 35° C (39 to 104° F) 
 
 
 
 
 
 
 
 
 49
4.2 METHODOLOGY  
 
In the present work an attempt was made to develop and validate a simple, 
precise and accurate methods for the estimation of Torsemide and Spironolactone in 
pure and in combined tablet dosage forms by UV- spectrophotometry and RP-HPLC 
methods. 
 The drugs were identified by checking the melting point of Torsemide and 
performing identification test for Spironolactone. 
4.2.1. UV-Spectrophotometry 
 
A. Simultaneous equation method 
B.  Absorbance ratio method 
C.  Derivative spectrophotometric method 
 
4.2.1.1 UV-Spectrophotometric method for the estimation of Torsemide 
 
4.2.2 RP-HPLC 
 
SPECTROSCOPIC METHODS 
 
4.2.1 SELECTION OF SOLVENT 
 
The solubility and stability for both Torsemide and Spironolactone were 
evaluated. The absorbance of both drugs were higher and exhibited distinct λmax in 
methanol followed by 0.02M phosphate buffer (pH-3.5) in the final dilution, since it 
was decided to prepare drug solutions in methanol followed by 0.02M phosphate 
buffer (pH-3.5). 
 
PREPARATION OF STANDARD STOCK SOLUTION 
 
Pure raw materials, Torsemide 100 mg and Spironolactone 100 mg were 
accurately weighed and dissolved separately in methanol to produce 1000 mcg/ml 
solution. 
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SELECTION OF WAVELENGTH 
 
The selection of wavelength for the estimation of Torsemide and 
Spironolactone, a suitable standard solution to contain 10 mcg/ml of Torsemide and 
Spironolactone were prepared individually and scanned in the entire range from 200-
400 nm, an overlain spectra was made. From the spectra, the λmax of Torsemide was 
found to be 289 nm and λmax of Spironolactone was found to be 242.5 nm. The 
Isobestic point was found to be 260.5 nm. Hence, the λmax of two drugs was selected 
for the simultaneous equation method. For the absorbance ratio method, the λmax of 
Spironolactone and Isobestic point were used. For Derivative Spectroscopic method, 
the zero order spectrum was derivatised to first order spectrum in that 310 nm was 
selected for the estimation of Torsemide, which is zero crossing for Spironolactone 
and 248.5 nm was selected for the estimation of Spironolactone which is zero crossing 
for Torsemide. 
 
 
LINEARITY AND CALIBRATION 
 
The linearity was carried out individually for both the drugs in zero order 
spectrum and first order spectrum at all above said wavelengths. The Beers law limit 
was found to be in the range of 4-20 mcg/ml. The calibration curves were obtained by 
plotting absorbance versus concentration of the standard solution. 
 
QUANTIFICATION IN FORMULATION 
 
Twenty tablets were weighed and average weight was found out and it was 
finely powdered. Powdered drug equivalent to 25 mg of Spironolactone was 
transferred in to a 25 ml standard flask and the content of the flask was dissolved in 
methanol by sonication for 15 minutes and then made up to the required volume. The 
solution was filtered through whatmann filter paper (No.41).The solution was diluted 
to get a concentration of 20 mcg/ml using Phosphate buffer (pH-3.5). Absorbance of 
the diluted sample solutions were measured for the methods as described in above 
said wavelengths. 
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VALIDATION 
 
PRECISION 
 
Precision of the method was demonstrated by repeatability studies. 
Repeatability studies were done by consequently analyzing the sample solution for six 
times. Intra day and inter day precision were established by repeating the 
determination on the same day and on different days respectively. 
 
RECOVERY STUDIES 
 
In order to ensure the accuracy of the proposed method recovery studies were 
carried out. To the pre analyzed sample solution, a definite concentration was added 
and then its recovery was studied. 1ml of  pre analyzed formulation was taken in three 
separate 10 ml volumetric flasks, with these, known concentration of pure drug 
(Torsemide and Spironolactone) at 60%, 80% and 100% levels were added. The 
absorbances of resulting solutions were measured at their corresponding wavelength 
and the percentage recovery was calculated. 
 
LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION 
 
Preparation of calibration curve from the serial dilution of standard was 
repeated for six times. The limit of detection and limit of quantification was 
calculated by using the average value of slope and standard deviation. 
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4.2.1.1 SPECTROSCOPIC METHOD FOR THE ESTIMATION OF 
TORSEMIDE  
 
To compare different brands of Torsemide a new analytical method has 
been developed 
 
SELECTION OF SOLVENT 
 
The solubility of Torsemide was determined in a variety of solvent. From the 
solubility studies 0.1N HCl was selected as a solvent based on stability of Torsemide. 
 
SELECTION OF λMAX 
 
The standard stock solution of Torsemide in 0.1N HCl was prepared. The 
standard stock solution was further diluted to get 10 mcg/ml solution. The solution 
was scanned between 200-400 nm wavelength range using 0.1N HCl as blank. From 
the UV spectra, 286.5 nm was selected as λmax for the analysis of Torsemide. 
 
LINEARITY AND CALIBRATION CURVE 
4 ml of stock solution (contains 1000 mcg/ml) was pipetted out into a 100 ml 
standard flask and the volume was made up to the mark with 0.1N HCl to get a 
concentration of 40 mcg/ml solution. The aliquots (1-8 ml) of working standard 
solution of Torsemide were transferred into a 10 ml standard flask and made up to the 
mark with 0.1N HCl. The absorbance was measured at 286.5 nm against 0.1N HCl as 
blank. The sample solutions were found to be linear from 4-32 mcg/ml. The 
calibration curve was plotted between concentration and absorbance. 
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QUANTIFICATION IN FORMULATIONS 
 
Four formulations were selected and twenty tablets of each formulation 
[(Torsinex 10mg), (Henletor 20mg), (Tide 10 mg) and (Dytor10 mg) were weighed to 
find out the average weight and powdered well. Transferred the powdered tablets 
equivalent to 25 mg of Torsemide into a 25 ml volumetric flask, sonicated for 15 
minutes and made up to the mark with 0.1N HCl. Half of the solution was filtered 
using whatmann filter paper No.41. The absorbance was measured at 286.5 nm using 
0.1 N HCl. The amount of Torsemide present in each formulation was calculated by 
using the slope and intercept values. 
 
RECOVERY STUDIES 
 
From each formulation of the pre-analyzed formulation, known quantities 
were taken and the raw material solution was added in ascending amount to 10 ml 
standard flask. The contents were mixed well, finally made up to the mark and 
filtered. The recovery studies for each formulation was calculated from slope and 
intercept values. 
 
4.2.2 HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD 
 
Chromatographic method depends up on the nature of the sample, molecular 
weight and solubility. The drug selected for the present study was polar compound; 
hence it can be separated either by normal phase or reverse phase chromatography. 
Reverse phase chromatographic technique was selected for initial separations with the 
knowledge of properties of compound, C18 column was chosen as stationary phase 
and a various ratios of phosphate buffer (pH 3.5), methanol and acetonitrile 
commonly considered as mobile phase. 
 
SELECTION OF MOBILE PHASE AND λMAX 
           Different mixtures of mobile phase with different ratios were selected like 
Acetonitrile: water (60:40), Phosphate buffer: methanol (60:40) and Phosphate buffer: 
Acetonitrile: methanol (40:40:20) and their chromatograms were recorded in Fig-6, 7 
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and 8. The above said mobile phase have not given sharp elution, but Phosphate 
buffer (pH 3.5): Acetonitrile: Methanol (40:30:30) was selected as a mobile phase 
since these two drugs were eluted with sharp peak and with better resolution.  Hence 
this mobile phase was used to optimize the chromatographic conditions.   
 
OPTIMIZED CHROMATOGRAPHIC CONDITIONS 
    The following parameters were used for RP-HPLC analysis of Torsemide 
and Spironolactone 
Mode of operation          - Isocratic 
Stationary phase             - C18 column (150mm × 4.6 mm I, d., 5m) 
Mobile phase                  - Phosphate buffer (pH 3.5): Methanol: Acetonitrile 
Ratio                               - 40:30:30 
Detection wavelength    - 262 
Flow rate                        - 1 ml/min 
Temperature                   - Ambient 
Sample volume               - 20 mcg/ml 
Operating pressure         - 150 kgf 
 
PREPARATION OF THE STANDARD STOCK SOLUTION 
 
Weighed accurately 25 mg of Torsemide and Spironolactone, transferred into 
a 25 ml standard flask separately and dissolved with minimum quantity of methanol 
and the volume was made up to the mark with methanol. From the above solutions,    
1 ml was transferred into a 10 ml flask to get the concentration of 100 mcg/ml. 
 
LINEARITY AND CALIBRATION 
 
From the standard solution, pipetted 0.5-2.5 ml into a series of five 10 ml flask 
and made up to the mark with mobile phase to obtain the concentration range from 5-
25 mcg/ml and the calibration curve was plotted between concentration and peak area. 
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QUANTIFICATION OF TORSEMIDE AND SPIRONOLACTONE 
 
Twenty tablets containing 10 mg of Torsemide and 50 mg of Spironolactone 
were accurately weighed and powdered tablets equivalent to 25 mg of Spironolactone 
was transferred to a 25 ml volumetric flask and dissolved in methanol and sonicated 
for 15 minutes. The final concentration was 1000 mcg/ml. From the above solution, a 
part was filtered through whatmann filter paper and the clear solution was collected, 
2.5 ml was pipetted into a 10 ml volumetric flask further diluted 1 ml to 10 ml and 
made up to the mark with mobile phase to produce 25 mcg/ml solution. The peak area 
measurements were done by injecting sample (20 mcg/ml) six times and the amount 
of Torsemide and Spironolactone were calculated from the respective calibration 
curve. 
 
RECOVERY STUDIES 
 
To ensure the reliability of the method, recovery studies were carried out by 
mixing a known quantity of standard drug solution with the pre-analyzed sample 
formulation and the content were mixed and made to the volume with mobile phase 
and re- analyzed by the proposed method, the percentage recovery was calculated. 
 
LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION 
 
Preparation of calibration curve for the serial dilution of standard was repeated 
for six times. The limit of detection and limit of quantification were calculated by 
using the average value of slope and standard deviation. 
 
SYSTEM SUITABILITY STUDIES 
 
The system suitability studies were carried out as specified in U.S.P. the 
parameter like column efficiency, tailing factor, asymmetric factor, theoretical plate 
number and capacity factor were calculated. 
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5. RESULTS AND DISCUSSION 
 
 
ABOUT UV SPECTROSCOPIC METHODS 
In order to quench the thirst for the analysis of a newer drug, the drug 
Torsemide and Spironolactone were taken for our studies. To ensure the percentage 
purity of Torsemide and Spironolactone in combined dosage form and various   
brands of Torsemide, the UV- spectroscopic methods were developed. The methods 
were very simple, economic and applicable for routine analysis. 
 
5.1 UV-SPECTROSCOPIC STUDIES 
 
The solubility of Torsemide and Spironolactone were determined in a variety 
of solvents using Schefter and Higuchi method. 10 mg of sample was taken in test 
tubes and checked with variety of solvents and their solubility profiles have been 
shown in Table-1. 
 
From the solubility studies, methanol followed by phosphate buffer (pH-3.5) 
was chosen as a solvent, for UV- spectroscopic studies in bulk and in formulations. 
Based upon its easy availability, cost factor and the stability conditions, the solvents 
were selected for the method. 
Three simple, sensitive and precise UV methods namely, Simultaneous 
Equation method, Absorbance Ratio method and Derivative Spectroscopic methods 
were preferred for the determination of Torsemide and Spironolactone in 
Pharmaceutical formulations. 
 
The drug was dissolved in methanol and followed by buffer to produce 10 
mcg/ml. It was scanned in the range of 200-400 nm and it shows constant λmax at 
289 nm for Torsemide and 242.5 nm for Spironolactone and overlain spectra was 
made. This is shown in Fig-1, 2 and 3. Stability of absorbance at their λmax was also 
checked. 
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The linearity of Torsemide and Spironolactone was constructed in the range of 
4-20 mcg/ml and its calibration curve is shown in the Fig-4 and 5. The optical 
characteristics such as Beer’s laws limit (4-20 mcg/ml), molar extinction co-efficient, 
Sandell’s sensitivity, correlation co-efficient, slope and intercept were calculated and 
are shown in Table-2. 
The Limit of detection and the Limit of quantification were determined from the 
linearity studies which was done 6 times and calculated by using slope and standard 
deviation. 
The formulations, Torlactone and Dytor+ were selected for analysis. The amount 
present were determined by average of six replicate analysis and the percentage purity 
was found to be in the range of 98.2-101.4% by all the three methods  and it is shown 
in Table- 3, 4 and 5. 
 
To evaluate the accuracy of the method, recovery studies were carried out, known 
amount of pure drug was added to the previously analyzed solution containing 
formulation and the mixture was reanalyzed by the proposed method and the 
recoveries were calculated. The percentage recovery of Torsemide and Spironolactone 
in the formulations viz Torlactone and Dytor+ were found to be in the range of 99.8-
102.4%.  Values are given in Table-6, 7 and 8. 
 
Precision of the method was studied by making repeated analysis of the same 
sample and it was carried out three times in a day for three days. The % RSD and 
standard deviation for inter-day and intra day analysis was found to be less than 2 
indicates the method is precise, which are given in Table 9 and 10. 
 
5.1.1 SPECTROSCOPIC METHODS FOR THE ESTIMATION OF 
TORSEMIDE 
 
The solubility of Torsemide was determined in number of solvents. From the 
solubility data, 0.1 N HCl was selected as solvent because of its good stability and 
easy availability. 
 
Different aliquots of Torsemide in 0.1 N HCl was prepared in the concentration 
range of 4-32 mcg/ml. The absorbance of solution was measured at 286.5 nm. 
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 The calibration curve was plotted using concentration against absorbance. The 
optical parameters like correlation co-efficient, slope, intercept, Sandell’s sensitivity, 
LOD and LOQ were calculated. These are shown in Table-11. 
 
 The correlation co-efficient value for the calibration curve was found to be 
0.9999. It indicates that the concentration of Torsemide with 0.1 N HCl has 
acceptable limit to proceed further studies. 
 
Torsemide containing tablets from four formulations [Torsinex 10 mg, Henletor 
20 mg, Tide 10 mg and Dytor 10 mg] were selected for analysis. The nominal 
concentration of Torsemide was prepared and the absorbances of the solution were 
measured at 286.5 nm.  
 
The amount of test solution was calculated by using slope and intercept values. 
This procedure was repeated for six times to ensure the precision of the method.  
 
The percentage label claims of Torsemide present in tablet formulations were 
found. The % RSD value was found to be ± 0.08412. The low % RSD value indicates 
that the method has good precision. The results of analysis are shown in the Table-12 
to 15. 
 
The accuracy of the method was performed by recovery studies. To the pre-
analyzed formulation, a known quantity of Torsemide raw material solution was 
added. 
 
 The absorbance of the solution was measured and the percentage recovery was 
calculated. The percentage recovery was found to be in the range of 100.2% 
to102.3%, with low % RSD values.  
 
It indicates that there is no interference due to excipients used in formulation. 
Hence the method was found to be accurate. The recovery data were shown in the 
Table-16 to 19. 
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5.2 RP-HPLC METHOD 
 
An effort has been made to identify a simple, cost effective, economic, 
specific and accurate method for the estimation of Torsemide and Spironolactone in 
formulation. 
 The  mobile phase with different ratios were selected like Acetonitrile: water 
(60:40), in this mobile phase the Rt is less than 2 minutes. Phosphate buffer: Methanol 
(60:40), here the peaks are very broad and Phosphate buffer: Acetonitrile: Methanol 
(40:40:20), these mobile phases have not given sharp elution of both drugs and also 
they are not in desired system suitability parameters. Hence the ratio was changed to 
40:30:30 of Phosphate buffer, methanol, acetonitrile respectively, this gives sharp 
elution and desired limits. 
 
The mobile phase which consists of Phosphate buffer (pH 3.5): Methanol: 
Acetonitrile was chosen in the ratio 40:30:30 based on its sharp elution and acceptable 
system suitability parameters. Detection of Torsemide and Spironolactone in mobile 
phase was found using UV-Visible detector at 262 nm, the flow rate was kept at 1 
ml/min. The retention time with optimum parameters were selected for the analytical 
studies.  
 
Optimization was done with the above mobile phase and various 
concentrations of raw material such as 5-25 mcg/ml of Torsemide and Spironolactone 
were prepared, injected and the chromatograms were recorded. This is shown in the 
Fig. 9-13. The optical characteristic such as Beer’s law limit (5-25 mcg/ml), 
correlation co-efficient, slope and intercept were calculated and shown in Table-20. 
The results were found to be satisfactory. The calibration curve for Torsemide and 
Spironolactone was plotted and shown in Fig-14 and 15. 
 
The limit of detection and the limit of quantification were determined by using 
slope and Standard Deviation. The LOD and LOQ were calculated. 
 
            The system suitability test parameters such as  Tailing factor, Theoretical plate 
per unit length and Asymmetric factor and resolution were calculated for the 
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concentration of 10 mcg/ml and are shown in Table-21, the parameters were found to 
be satisfactory as per guidelines.  
The formulation Dytor+ was selected for the analysis. The Tablet powder 
equivalent to 25 mg of Spironolactone was taken and 25 mcg/ml concentration was 
prepared and injected. Injection repeatability was performed for the same 
concentration six times and amount present was found to be 100.2 % and 98.5 % for 
Torsemide and Spironolactone respectively. The values are shown in the Table -22, 
hence the precision was confirmed by repeatable injection of formulation and their 
chromatograms are shown in the Fig-16 to 21. 
 
              Accuracy was confirmed by recovery studies, by adding known amount of 
pure drug to the previously analyzed formulation and the mixture was reanalyzed by 
the proposed method and it is shown in the Fig-22 to 24. The percentage recovery of 
Dytor+ was found to be 102.2% and 100.5% for Torsemide and Spironolactone 
respectively. The values are given in Table-23. The proposed method was validated 
and found that the excipients and additives did not interfering the developed method. 
 
All the above parameters combined with simplicity and easy of operation 
ensures that the application of the proposed method for the assay of drug in 
Pharmaceutical dosage forms. 
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       6. SUMMARY AND CONCLUSION 
 
 Torsemide is a pyridine-sulfonylurea type loop Diuretic mainly used in the 
management of oedema associated with Congestive Heart Failure. It is also used at 
low doses for the management of hypertension. Spironolactone is a powerful 
aldosterone antagonist.  
 
The proposed analytical methods are simple, economical, rapid, sensitive, 
reproducible and accurate for the estimation of Torsemide and Spironolactone. The 
methods adopted for studies were 
 
1.  UV- spectroscopic method for the estimation of Torsemide and Spironolactone in 
combined dosage form by 
 Simultaneous equation method 
 Absorbance ratio method 
 Derivative spectroscopic method 
2. UV-spectroscopic method for the estimation of Torsemide in different 
formulations. 
3. RP-HPLC method for the estimation of Torsemide and Spironolactone in combined 
dosage form. 
 
The drug samples containing Torsemide and Spironolactone in combined 
dosage form were analyzed by UV-spectroscopic method using methanol followed by 
0.02 M Phosphate buffer (pH-3.5) as a solvent and the content of drug present in each 
formulations (Torlactone and Dytor+) were found to be satisfactory. 
 
The estimation of Torsemide containing tablets by UV-spectroscopic method 
using 0.1N HCl was done and four formulations were selected [Torsinex 10 mg, 
Henletor 20 mg, Tide 10 mg and Dytor 10 mg]. The results were found to be 
satisfactory. 
 
Simultaneously, a newer RP-HPLC method has been developed for the 
estimation of both drugs in bulk and in formulation. The proposed method gives 
reliable assay results with short analysis time using mobile phase phosphate buffer 
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(pH 3.5): Methanol: Acetonitrile in the ratio of 40:30:30 respectively. The content of 
drug present in the formulation (DYTOR+) was found to be satisfactory and system 
suitability parameters are in desired limit. 
 
All the above methods do not suffer from any interference due to common 
excipients. It indicates that the methods were accurate. Therefore the proposed 
methods could be successfully applied to estimate commercial pharmaceutical 
products containing Torsemide and Spironolactone.  
 
Thus the above studies and findings are helpful to the analytical chemists to 
apply the analytical methods for the routine analysis of the analyte in Pharmaceutical 
dosage forms with the approval of FDA. 
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FIGURE-1 
 
UV-SPECTRUM OF TORSEMIDE 
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FIGURE-2 
 
UV-SPECTRUM OF SPIRONOLACTONE 
 
 
 
 
 
 Wavelength (nm) 
 
 
 
 
 
 
 
 
 
A
bs
o
rb
an
ce
 
 68
FIGURE -3 
OVERLAIN SPECTRUM OF TORSEMIDE AND SPIRONOLACTONE 
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FIGURE-4 
 CALIBRATION CURVE FOR TORSEMIDE 
 
 
 
 
FIGURE-5 
 CALIBRATION CURVE FOR SPIRONOLACTONE 
 
 
 
 
CALIBRATION CURVE
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0 5 10 15 20 25
CONCENTRATION(mcg/ml)
A
BS
O
R
B
A
N
C
E
 
 
 
 
CALIBRATION CURVE
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
0 5 10 15 20 25
CONCENTRATION (mcg/ml) 
A
B
SO
R
BA
N
C
E 
 70
FIGURE-6 
 
OPTIMIZATION OF CHROMATOGRAM USING PHOSPHATE BUFFER: 
METHANOL (60:40) 
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FIGURE-7 
 
OPTIMIZATION OF CHROMATOGRAM USING ACETONITRILE (pH-3): 
WATER (60:40) 
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FIGURE-8 
 
OPTIMIZATION OF CHROMATOGRAM USING ACETONITRILE: 
METHANOL: PHOSPHATE BUFFER (pH-3.5) 
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FIGURE-9 
 
LINEARITY CHROMATOGRAM OF TORSEMIDE AND 
SPIRONOLACTONE (5 MCG/ML) 
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FIGURE-10 
 
LINEARITY CHROMATOGRAM OF TORSEMIDE AND 
SPIRONOLACTONE (10 MCG/ML) 
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FIGURE -11 
 
LINEARITY CHROMATOGRAM OF TORSEMIDE AND 
SPIRONOLACTONE (15 MCG/ML) 
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FIGURE-12 
 
LINEARITY CHROMATOGRAM OF TORSEMIDE AND 
SPIRONOLACTONE (20 MCG/ML) 
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FIGURE-13 
 
LINEARITY CHROMATOGRAM OF TORSEMIDE AND 
SPIRONOLACTONE (25 MCG/ML) 
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FIGURE-14 
 
CALIBRATION CURVE FOR TORSEMIDE BY RP-HPLC 
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FIGURE-15 
 
 
CALIBRATION CURVE FOR SPIRONOLACTONE BY RP-HPLC 
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FIGURE-16 
 
QUANTIFICATION OF TORSEMIDE AND SPIRONOLACTONE IN 
FORMULATION 
 
 
 
 
 
 
 
 
 
 
 80
FIGURE-17 
 
QUANTIFICATION OF TORSEMIDE AND SPIRONOLACTONE IN 
FORMULATION 
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FIGURE-18 
 
QUANTIFICATION OF TORSEMIDE AND SPIRONOLACTONE IN 
FORMULATION 
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FIGURE-19 
 
QUANTIFICATION OF TORSEMIDE AND SPIRONOLACTONE IN 
FORMULATION 
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FIGURE-20 
 
QUANTIFICATION OF TORSEMIDE AND SPIRONOLACTONE IN 
FORMULATION 
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FIGURE-21 
 
QUANTIFICATION OF TORSEMIDE AND SPIRONOLACTONE IN 
FORMULATION 
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FIGURE-22 
 
RECOVERY STUDIES OF TORSEMIDE AND SPIRONOLACTONE BY RP-
HPLC 
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FIGURE-23 
 
RECOVERY STUDIES OF TORSEMIDE AND SPIRONOLACTONE BY RP-
HPLC 
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FIGURE-24 
 
RECOVERY STUDIES OF TORSEMIDE AND SPIRONOLACTONE BY RP-
HPLC 
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TABLE-1 
 
 
 
SOLUBILITY OF TORSEMIDE AND SPIRONOLACTONE IN VARIOUS 
SOLVENTS 
 
 
 
 
SOLVENT     TOR EXTENT 
OF  
SOLUBILIT
Y 
      SPI EXTENT 
OF  
SOLUBILIT
Y 
ACETONITRIL
E 
 
ACETONE 
 
ACETIC ACID 
 
BENZENE 
 
CHLOROFOR
M 
 
ETHANOL 
 
0.1 N HCl 
 
0.1 M NAOH 
 
METHANOL 
 
WATER 
SOLUBLE 
 
INSOLUBL
E 
 
SOLUBLE 
 
INSOLUBL
E 
 
INSOLUBL
E 
 
SOLUBLE 
 
SOLUBLE 
 
SOLUBLE 
 
SOLUBLE 
 
INSOLUBL
E 
10 mg in 7 ml 
 
----- 
 
10 mg in 8 ml 
 
----- 
 
----- 
 
10 mg in 5 ml 
 
10 mg in 2 ml 
 
10 mg in 6 ml 
 
10 mg in 4 ml 
 
------ 
SOLUBLE 
 
SOLUBLE 
 
SOLUBLE 
 
SOLUBLE 
 
SOLUBLE 
 
SOLUBLE 
 
INSOLUBL
E 
 
INSOLUBL
E 
 
SOLUBLE 
 
INSOLUBL
E 
10 mg in 1 ml 
 
10 mg in 1 ml 
 
10 mg in 2 ml 
 
10 mg in 3 ml 
 
10 mg in 1 ml 
 
10 mg in 5 ml 
 
------ 
 
------ 
 
10 mg in 7 ml 
 
-------- 
          TOR is Torsemide 
          SPI is Spironolactone 
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TABLE-2 
 
OPTICAL CHARACTERISTICS OF TORSEMIDE AND 
SPIRONOLACTONE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PARAMETERS 
 
 
TORSEMIDE 
 
SPIRONOLACTONE 
 
Beer’s law limits 
 
 
4-20 µg/ml 
 
4-20  µg/ml 
 
Molar absorptivity 
(L/mol/cm) 
 
 
15248.312 
 
22547.53 
 
Slope (m) 
 
 
0.043430714 
 
0.052402381 
 
Intercept (c) 
 
 
0.004697373 
 
0.008902093 
 
Correlation- 
Co-efficient (r) 
 
 
0.9998 
 
0.9999 
 
Sandell’s sensitivity 
(mg/cm²/0.001A.v) 
 
0.023025183 
 
0.019091411 
           
            LOD 
 
 
0.356920928 
 
0.560602522 
 
LOQ 
 
  
 1.081578569 
 
1.698795523 
 
Standard Error 
 
 
0.001676174 
 
0.0004120123 
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TABLE-3 
 
ASSAY OF COMMERCIAL FORMULATION BY UV- SPECTROSCOPY 
(SIMULTANEOUS EQUATION METHOD) 
 
 
Formulation 
 
 
Dru
g 
 
S.No
. 
Amount 
Labeled 
(mg/tab
) 
Amount 
Estimate
d 
(mg/tab) 
% 
Amoun
t 
found 
 
S.D. 
(+/-) 
 
 
R.S.D
. 
 
S.E. 
 
 
 
 
 
 
TORLACTON
E 
 
 
 
TO
R 
 
 
 
 
 
 
SPI 
1 
2 
3 
4 
5 
6 
 
1 
2 
3 
4 
5 
6 
 
 
10 
 
 
 
 
 
 
50 
9.836 
9.993 
9.774 
10.59 
10.11 
9.893 
 
50.88 
49.13 
50.47 
49.8 
49.54 
48.81 
98.36 
99.36 
97.74 
105.9 
101.1 
98.93 
 
101.3 
98.81 
104.7 
99.87 
99.46 
98.12 
 
 
0.97
7 
 
 
 
 
 
 
0.86
3 
 
 
0.978 
 
 
 
 
 
 
 0.86 
 
 
0.39
8 
 
 
 
 
 
 
0.37
8 
 
 
 
 
 
 
 
DYTOR+ 
 
 
 
 
 
 
 
 
 
TO
R 
 
 
 
 
 
 
SPI 
1 
2 
3 
4 
5 
6 
 
1 
2 
3 
4 
5 
6 
 
 
20 
 
 
 
 
 
 
50 
20.89 
19.14 
20.58 
19.47 
19.36 
19.83 
 
50.14 
50.48 
48.91 
49.45 
49.81 
49.31 
104.4 
95.73 
102.9 
97.35 
96.87 
99.15 
 
100.2 
100.9 
97.82 
98.91 
99.63 
98.63 
 
 
1.14
7 
 
 
 
 
 
 
0.86 
 
 
 
1.154 
 
 
 
 
 
 
0.960 
 
 
0.81
1 
 
 
 
 
 
 
0.55 
TOR is Torsemide 
SPI is Spironolactone 
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TABLE-4 
 
ASSAY OF COMMERCIAL FORMULATION BY UV-SPECTROSCOPY 
(ABSORBANCE RATIO METHOD) 
 
 
Formulation 
 
Drug 
 
S.No. 
Amount 
Labeled 
(mg/tab) 
Amount 
Estimated 
(mg/tab) 
% 
Amount 
found 
 
S.D. 
(+/-) 
 
 
R.S.D. 
 
S.E. 
 
 
 
 
 
 
TORLACTONE 
 
 
 
 
TOR 
 
 
 
 
 
 
SPI 
1 
2 
3 
4 
5 
6 
 
1 
2 
3 
4 
5 
6 
 
 
10 
 
 
 
 
 
 
50 
 
 
 
9.833 
10.13 
10.38 
9.711 
9.965 
10.03 
 
50.89 
48.25 
49.88 
47.22 
51.45 
49.96 
98.33 
101.3 
103.8 
97.11 
99.65 
100.3 
 
100.8 
98.25 
98.42 
97.51 
101.3 
98.96 
 
 
0.88 
 
 
 
 
 
 
0.70 
 
 
0.88 
 
 
 
 
 
 
0.71 
 
 
0.51 
 
 
 
 
 
 
0.40 
 
 
 
 
 
 
DYTOR+ 
 
 
TOR 
 
 
 
 
 
 
SPI 
1 
2 
3 
4 
5 
6 
 
1 
2 
3 
4 
5 
6 
 
 
20 
 
 
 
 
 
 
50 
19.69 
20.31 
19.17 
20.38 
20.83 
19.35 
 
49.69 
51.55 
47.24 
49.81 
49.25 
50.91 
98.45 
101.5 
95.85 
101.9 
104.1 
96.25 
 
99.38 
103.1 
94.48 
99.62 
98.55 
101.8 
 
 
0.69 
 
 
 
 
 
 
1.31 
 
 
0.70 
 
 
 
 
 
 
1.32 
 
 
0.40 
 
 
 
 
 
 
0.75 
TOR is Torsemide 
SPI is Spironolactone 
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TABLE-5 
 
ASSAY OF COMMERCIAL FORMULATION BY UV-SPECTROSCOPY 
(DERIVATIVE SPECTROSCOPY METHOD) 
 
 
Formulation 
 
Drug 
 
S.No 
Amount 
Labeled 
(mg/tab) 
Amount 
Estimated 
(mg/tab) 
% 
Amount 
found 
 
S.D. 
(+/-) 
 
 
R.S.D. 
 
S.E. 
 
 
TORLACTONE 
 
 
TOR 
 
 
 
 
 
 
SPI 
1 
2 
3 
4 
5 
6 
 
1 
2 
3 
4 
5 
6 
 
 
 10 
 
 
 
 
 
 
  50 
9.89 
10.16 
9.62 
10.43 
9.83 
10.18 
 
50.36 
50.41 
49.81 
48.21 
48.44 
51.21 
98.93 
101.6 
96.2 
104.3 
98.33 
101.8 
 
100.3 
100.4 
98.12 
98.72 
98.74 
102.7 
 
 
1.7 
 
 
 
 
 
 
0.46 
 
 
1.07 
 
 
 
 
 
 
0.46 
 
 
0.43 
 
 
 
 
 
 
0.18 
 
 
 
 
 
 
DYTOR+ 
 
 
TOR 
 
 
 
 
 
 
SPI 
1 
2 
3 
4 
5 
6 
 
1 
2 
3 
4 
5 
6 
 
 
20 
 
 
 
 
 
 
50 
20.81 
19.38 
20.34 
19.26 
20.16 
19.98 
 
51.12 
48.41 
49.21 
49.91 
50.63 
50.41 
104.5 
96.90 
101.7 
96.3 
100.8 
99.93 
 
102.2 
96.82 
98.42 
99.82 
101.2 
100.8 
 
 
 
2.02 
 
 
 
 
 
 
1.42 
 
 
2.01 
 
 
 
 
 
 
1.43 
 
 
0.43 
 
 
 
 
 
 
0.82 
TOR is Torsemide 
SPI is Spironolactone 
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TABLE -6 
 
RECOVERY STUDIES –SIMULTANEOUS EQUATION METHOD 
 
 
Formulation 
 
Drug 
 
S.No. 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Found 
(µg/ml) 
Amount 
Recovered 
(µg/ml) 
    % 
Recovery 
 
 
 
TORLACTONE 
 
TOR 
 
 
 
SPI 
1 
2 
3 
 
1 
2 
3 
0.8 
0.8 
0.8 
 
4 
4 
4 
4 
6 
8 
 
4 
6 
8 
4.78 
6.91 
8.85 
 
7.94 
10.5 
12.23 
3.98 
6.10 
8.05 
 
3.94 
6.05 
8.23 
99.54 
101.6 
100.6 
 
98.52 
100.8 
102.9 
 
 
 
DYTOR+ 
 
TOR 
 
 
 
SPI 
1 
2 
3 
 
1 
2 
3 
1.6 
1.6 
1.6 
 
4 
4 
4 
4 
6 
8 
 
4 
6 
8 
 
5.73 
7.58 
9.59 
 
8.41 
9.87 
12.1 
4.13 
5.98 
7.99 
 
4.11 
5.87 
8.19 
103.2 
99.68 
99.87 
 
101.2 
97.83 
102.3 
TOR is Torsemide 
SPI is Spironolactone 
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TABLE -7 
 
RECOVERY STUDIES–ABSORBANCE RATIO METHOD 
 
 
Formulation 
 
Drug 
 
S.No. 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Found 
(µg/ml) 
Amount 
Recovered 
(µg/ml) 
     % 
Recovery 
 
 
 
TORLACTONE 
 
TOR 
 
 
 
SPI 
1 
2 
3 
 
1 
2 
3 
0.8 
0.8 
0.8 
 
4 
4 
4 
4 
6 
8 
 
4 
6 
8 
4.96 
6.71 
8.98 
 
7.64 
10.21 
12.01 
4.16 
5.91 
8.81 
 
3.64 
6.21 
8.01 
104.8 
98.5 
102.2 
 
96.5 
103.5 
101.2 
 
 
 
DYTOR+ 
 
TOR 
 
 
 
SPI 
1 
2 
3 
 
1 
2 
3 
1.6 
1.6 
1.6 
 
4 
4 
4 
4 
6 
8 
 
4 
6 
8 
 
5.67 
7.54 
9.61 
 
8.04 
10.51 
11.39 
4.07 
5.94 
8.01 
 
4.04 
6.51 
7.39 
 
101.3 
96.25 
99.6 
 
101.1 
108.5 
92.37 
TOR is Torsemide 
SPI is Spironolactone 
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TABLE -8 
 
RECOVERY STUDIES –DERIVATIVE SPECTROSCOPY METHOD 
 
 
 
Formulation 
 
Drug 
 
S.No. 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Found 
(µg/ml) 
Amount 
Recovered 
(µg/ml) 
% 
Recovery 
 
 
 
TORLACTONE 
 
TOR 
 
 
 
SPI 
1 
2 
3 
 
1 
2 
3 
0.8 
0.8 
0.8 
 
4 
4 
4 
4 
6 
8 
 
4 
6 
8 
4.85 
6.91 
8.91 
 
7.89 
10.22 
12.41 
4.05 
6.11 
8.11 
 
3.89 
6.22 
8.41 
101.5 
101.8 
101.3 
 
97.25 
103.66 
105.12 
 
 
 
DYTOR+ 
 
TOR 
 
 
 
SPI 
1 
2 
3 
 
1 
2 
3 
1.6 
1.6 
1.6 
 
4 
4 
4 
4 
6 
8 
 
4 
6 
8 
5.54 
7.71 
9.90 
 
8.21 
9.94 
11.89 
3.94 
6.11 
8.3 
 
4.21 
5.94 
7.89 
98.5 
101.8 
103.7 
 
105.2 
99.5 
98.86 
TOR is Torsemide 
SPI is Spironolactone 
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TABLE-9 
 
PRECISION (INTERDAY) 
 
 
Formulation 
 
Drug 
 
S.No. 
Amount 
Labeled 
(mg/tab) 
Amount 
Estimated 
(mg/tab) 
% 
Amount 
found 
 
S.D 
(+/-) 
 
 
R.S.D 
 
S.E 
 
 
 
TORLACTONE 
 
TOR 
 
 
 
SPI 
1 
2 
3 
 
1 
2 
3 
 
10 
 
 
 
50 
9.833 
10.13 
10.38 
 
50.89 
48.25 
49.88 
98.33 
101.3 
103.8 
 
100.8 
98.25 
98.42 
 
1.33 
 
 
 
0.98 
 
 
1.03 
 
 
 
0.99 
 
0.76 
 
 
 
0.56 
 
 
 
DYTOR+ 
 
TOR 
 
 
 
SPI 
1 
2 
3 
 
1 
2 
3 
 
20 
 
 
 
50 
19.69 
20.31 
19.17 
 
49.69 
51.55 
47.24 
98.45 
101.5 
95.85 
 
99.38 
103.1 
94.62 
 
0.11 
 
 
 
0.24 
 
0.13 
 
 
 
0.24 
 
0.06 
 
 
 
0.12 
TOR is Torsemide 
SPI is Spironolactone 
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TABLE-10 
 
PRECISION (INTRADAY) 
  
 
Formulation 
 
Drug 
 
S.No. 
Amount 
Labeled 
(mg/tab) 
Amount 
Estimated 
(mg/tab) 
% 
Amount 
found 
 
S.D 
(+/-) 
 
 
R.S.D 
 
S.E 
 
 
 
TORLACTONE 
 
TOR 
 
 
 
SPI 
1 
2 
3 
 
1 
2 
3 
 
10 
 
 
 
50 
9.711 
9.96 
10.03 
 
50.89 
48.25 
49.88 
97.11 
99.65 
100.3 
 
100.8 
98.25 
98.96 
 
0.67 
 
 
 
0.88 
 
0.64 
 
 
 
0.83 
 
0.31 
 
 
 
0.34 
 
 
 
DYTOR+ 
 
TOR 
 
 
 
SPI 
1 
2 
3 
 
1 
2 
3 
 
20 
 
 
 
50 
19.69 
20.38 
20.83 
 
49.81 
49.25 
50.91 
98.54 
101.9 
104.2 
 
99.62 
98.5 
101.8 
 
1.74 
 
 
 
0.20 
 
1.43 
 
 
 
0.21 
 
0.58 
 
 
 
0.19 
TOR is Torsemide 
SPI is Spironolactone 
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TABLE-11 
 
OPTICAL CHARACTERISTICS OF TORSEMIDE IN 0.1 N HCL 
 
 
 
 
PARAMETERS 
 
 
 
            TORSEMIDE 
 
 
λ max 
 
Beer’s law limit(µg/ml) 
 
Sandell’s  sensitivity 
(mg/cm²/0.001A.v) 
 
Molar absorptivity (1/mol/cm) 
 
Correlation Co- efficient 
 
Slope    (m) 
 
Intercept (c) 
 
LOD (µg/ml) 
 
LOQ  (µg/ml) 
 
 
 
286.5 
 
4-32 µg/ml 
 
0.027923211 
 
 
12866.451 
 
0.9998 
 
0.0355776950 
 
0.00199851301 
 
0.15775 
 
0.47804 
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TABLE -12 
 
QUANTIFICATION OF TORSEMIDE IN FORMULATION-1 (TORSINEX) 
 
 
S.NO. LABLE 
CLAIM 
AMOUNT 
OBTAINED 
% 
OBTAINED 
AVERAGE % R.S.D 
1 10 mg 9.851 98.51   
2 10 mg 9.795 97.99   
3 10 mg 9.781 98.84 98.79 % 0.1984816 
4 10 mg 9.865 98.65   
5 10 mg 9.893 98.93   
6 10 mg 9.937 99.87   
 
 
 
 
 
 
 
 
  
 
TABLE -13 
 
QUANTIFICATION OF TORSEMIDE IN FORMULATION-2 (HENLETOR) 
 
S.NO. LABLE 
CLAIM 
AMOUNT 
OBTAINED 
% 
OBTAINED 
AVERAGE % R.S.D 
1 20 mg 19.865 99.328   
2 20 mg 19.647 98.235   
3 20 mg 19.759 98.798 99.123% 0.1565388 
4 20 mg 19.731 99.518   
5 20 mg 19.703 98.518   
6 20 mg 19.731 98.65   
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Table -14 
 
QUANTIFICATION OF TORSEMIDE IN FORMULATION-3 (TIDE) 
 
 
S.NO. LABLE 
CLAIM 
AMOUNT 
OBTAINED 
% 
OBTAINED 
AVERAGE % R.S.D 
1 10 mg 9.950 99.500   
2 10 mg 9.906 99.063   
3 10 mg 9.893 99.938 98.935% 0.08412566 
4 10 mg 9.893 98.936   
5 10 mg 9.865 98.657   
6 10 mg 9.851 98.916   
 
 
 
 
 
 
 
 
 
Table-15 
 
QUANTIFICATION OF TORSEMIDE IN FORMULATION-4 (DYTOR) 
 
 
S.NO. LABLE 
CLAIM 
AMOUNT 
OBTAINED 
% 
OBTAINED 
AVERAGE % R.S.D 
1 10 mg 9.950 99.500   
2 10 mg 9.925 99.925   
3 10 mg 9.950 99.500 99.488% 0.06371167 
4 10 mg 9.913 99.135   
5 10 mg 9.903 99.086   
6 10 mg 9.925 99.253   
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Table-16 
 
RECOVERY STUDIES OF TORSEMIDE IN FORMULATION (TORSINEX) 
 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Estimated 
(µg/ml) 
Amount 
Recovered 
(µg/ml) 
 
% 
Recovery 
 
Average 
 
10.027 
9.9219 
9.5288 
10.027 
 
 
2.5 
5.0 
7.5 
10 
 
12.76 
14.92 
17.45 
19.78 
 
2.49 
4.99 
7.92 
9.76 
 
99.6 
    99.8 
104.66 
97.60 
 
 
101.49 
% 
 
 
 
 
 
 
 
 
 
Table-17 
 
RECOVERY STUDIES OF TORSEMIDE IN FORMULATION (HENLETOR) 
 
 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Estimated 
(µg/ml) 
Amount 
Recovered 
(µg/ml) 
 
     % 
Recovery 
 
Average 
 
19.73 
19.64 
19.75 
 
 
 
4 
8 
12 
 
24.06 
27.57 
31.08 
 
4.32 
7.93 
11.32 
 
108.21 
99.12 
94.44 
 
 
100.59 
    % 
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Table-18 
 
RECOVERY STUDIES OF TORSEMIDE IN FORMULATION (TIDE) 
 
 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Estimated 
(µg/ml) 
Amount 
Recovered 
(µg/ml) 
 
% 
Recovery 
 
Average 
 
19.89 
19.85 
19.86 
 
 
 
4 
8 
12 
 
24.28 
27.22 
32.84 
 
4.39 
7.37 
12.98 
 
109.18 
95.21 
108.62 
 
 
104.34 
% 
 
 
 
 
 
 
Table-19 
 
RECOVERY STUDIES OF TORSEMIDE IN FORMULATION (DYTOR) 
 
 
 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
estimated 
(µg/ml) 
Amount 
Recovered 
(µg/ml) 
 
% 
Recovery 
 
Average 
 
19.95 
19.92 
19.95 
 
 
 
4 
8 
12 
 
24.11 
27.51 
32.60 
 
4.16 
7.59 
12.65 
 
105.41 
94.87 
105.87 
 
 
101.97 
% 
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TABLE-20 
OPTICAL CHARECTERSTICS OF TORSEMIDE AND SPIRONOLACTONE 
BY RP-HPLC METHOD 
 
 
 
PARAMETERS 
 
 
 
            TORSEMIDE 
 
 
 
SPIRONOLACTONE 
 
λ max 
 
Beer’s law limit (µg/ml) 
 
Correlation Co- efficient 
 
Slope    (m) 
 
Intercept (c) 
 
LOD (µg/ml) 
 
LOQ  (µg/ml) 
 
Standard Error 
 
 
 
262 
 
5-25 
 
0.9998 
 
272159.04 
 
30617.3 
 
0.1919119 
 
0.581549668 
 
329160.45 
 
262 
 
5-25 
 
0.9999 
 
187484.83 
 
-5990.75 
 
0.62941843 
 
1.9073285 
 
209542.88 
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TABLE -21 
SYSTEM SUITABILITY PARAMETERS FOR THE OPTIMIZED 
CHROMATOGRAM BY RP – HPLC METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PARAMETERS TORSEMIDE SPIRONOLACTONE 
Tailing factor     1.30     1.22 
Asymmetrical factor     1.44     1.33 
Capacity factor     0.82     4.37 
Theoretical plate per unit 
length 
   36.26    53.54 
Resolution 18.02 
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TABLE-22 
ASSAY OF COMMERCIAL FORMULATION (DYTOR+) BY RP-HPLC 
METHOD 
DRUG SAMPLE 
NO. 
LABELED 
AMOUNT 
(mg/tab) 
AMOUNT 
FOUND 
(mg/tab) 
PERCENTAGE 
OBTAINED 
AVERAGE 
% 
S.D. 
(+/-) 
% 
R.S.D. 
 
 
TOR 
 
1 
2 
3 
4 
5 
6 
10 
10 
10 
10 
10 
10 
10.44 
10.26 
10.48 
9.932 
9.442 
9.72 
104.4 
102.6 
104.8 
99.32 
94.48 
97.2 
 
 
100.45 
 
 
0.54 
 
 
0.51 
 
 
SPI 
1 
2 
3 
4 
5 
6 
50 
50 
50 
50 
50 
50 
50.32 
49.50 
50.56 
47.86 
45.84 
48.3 
100.64 
99.01 
101.12 
95.72 
94.68 
96.6 
 
 
98.96 
 
 
0.76 
 
 
0.71 
TOR is Torsemide 
SPI is Spironolactone 
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TABLE – 23 
RECOVERY STUDIES OF TORSEMIDE AND SPIRONOLACTONE BY 
 RP-HPLC METHOD 
 
TOR is Torsemide 
SPI is Spironolactone 
 
 
 
 
 
 
 
 
 
DRUG 
% 
LEVEL 
AMOUNT 
PRESENT 
(µg/ml) 
AMOUNT 
ADDED 
(µg/ml) 
AMOUNT 
ESTIMATED 
(µg/ml) 
AMOUNT 
RECOVERED 
% 
RECOVERY 
S.D. 
(+/-) 
 
% 
R.S.D. 
 
TOR 
150 
200 
250 
2.5 
2.5 
2.5 
5 
7.5 
10 
7.876 
11.34 
11.19 
2.876 
6.34 
6.19 
105.01 
113.4 
89.54 
 
1.93 
 
1.88 
 
SPI 
100 
120 
130 
12.5 
12.5 
12.5 
2.5 
5 
7.5 
14.94 
17.69 
19.98 
2.45 
5.19 
7.48 
99.96 
101.18 
99.90 
 
0.43 
 
0.43 
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